Vitamin D Supplementation Is Associated With Stabilization of Cardiac Autonomic Tone in IgA Nephropathy

Michelle C. Mann, Brenda R. Hemmelgarn, Derek V. Exner, David A. Hanley, Tanvir C. Turin, David C. Wheeler, Darlene Y. Sola, Linda Ellis, Sofia B. Ahmed

To the Editor:

Vitamin D deficiency is a cardiovascular risk factor.1-3 Deficiency in both 25-hydroxy vitamin D, the barometer of vitamin D status, and the more biologically active 1,25-dihydroxy vitamin D is associated with increased risk of sudden cardiac death (SCD).4-5 particularly in the chronic kidney disease (CKD) population.4,5 Studies have suggested that vitamin D supplementation may alter SCD risk by influencing activity of the cardiac autonomic nervous system, although this phenomenon has not been studied in the CKD population.5

Assessment of heart rate variability, including derivations of cardiac autonomic tone (CAT), provides predictive measures of cardiovascular risk, namely through quantification of the electric output of the cardiac autonomic nervous system.6 Patients with CKD show a marked withdrawal of parasympathetic tone,7 a strong indicator of loss of cardioprotective control and a risk factor for SCD.6 Alterations in CAT are attenuated by renin–angiotensin system (RAS)–interrupting medications, such as angiotensin-converting enzyme inhibitors.8 Given that vitamin D is a negative regulator of the RAS9 and supplementation with oral vitamin D3 is associated with improvements in CAT in humans with CKD due to IgA nephropathy, we sought to determine whether oral vitamin D3 supplementation was associated with a similar improvement in CAT in humans with CKD due to IgA nephropathy.

This study was approved by the Conjoint Health Research Ethics Board at the University of Calgary, and all subjects provided written informed consent. Fifteen subjects (87% men, 41±4 years) with IgA nephropathy (estimated glomerular filtration rate: 101±7 mL/min per 1.73 m2; proteinuria: 1.03±0.3 g/d) were studied after an overnight fast in high-salt balance before and after 28 days of vitamin D3 supplementation (10,000 IU/d). CAT, quantified by spectral analysis of heart rate variability (low-frequency power [LF], high-frequency power [HF], and overall cardiac autonomic activity [LF:HF]), was measured at baseline and in response to a graded angiotensin-II (Ang-II) challenge (3 ng/kg per min×30 min, 6 ng/kg per min; recovery) before and after 28 days of vitamin D3 supplementation (10,000 IU/d). CAT responses to Ang-II and during recovery (Figure). In comparison, after vitamin D3 supplementation, subjects displayed significantly decreased LF:HF in response to graded Ang-II infusion and during recovery (ΔLF:HF: 3 ng/kg per min Ang-II, −0.21±0.14, P=0.04; 6 ng/kg per min Ang-II, −0.21±0.11, P=0.03; recovery, −0.14±0.07, P=0.035 versus presupplementation response; Figure), largely because of a decline in measures of LF, most notably during recovery (ΔLF [nu]: recovery, P=0.014 versus presupplementation response). Blood pressure and circulating RAS components responded to Ang-II as expected, although no differences in any parameters were observed before and after vitamin D3 supplementation.

Secondary analyses with repeated measures ANOVA showed that intraindividual differences in 1,25-dihydroxy vitamin D levels appeared to account for the observed divergence in CAT responses over the 3 time points during and after Ang-II challenge (3 ng/kg per min, 6 ng/kg per min; recovery). Before supplementation, individuals with levels of 1,25-dihydroxy vitamin D below the median value of 105 pmol/L demonstrated a decline in parasympathetic tone throughout Ang-II challenge and recovery, whereas those with 1,25-dihydroxy vitamin D levels above 105 pmol/L showed a favorable and graded increase in cardioprotective parasympathetic activity in response to increasing doses of Ang-II throughout the study irrespective of 25-hydroxy vitamin D levels. After 4 weeks of oral vitamin D3 supplementation, 1,25-dihydroxy vitamin D levels above the postsupplementation median value (120 pmol/L) remained strongly associated with the same significant trend of steadily increasing parasympathetic activity in response to Ang-II challenge and recovery (HF [nu]: F=6.96; df=1; P=0.039).
In a post hoc analysis, baroreflex sensitivity was analyzed in a subgroup of subjects (n=5; 1 woman and 4 men) with adequate baroreflex sensitivity measurement as a secondary measure of parasympathetic activity. Although not statistically significant, there was a trend toward increased baroreflex sensitivity after vitamin D3 supplementation as throughout Ang-II challenge, baroreflex sensitivity followed the same trend as measured HF (Table).

To the best of our knowledge, this is the first study investigating the effect of vitamin D supplementation on CAT, a potentially modifiable marker of cardiovascular risk, in patients with CKD. Our key findings are as follows: (1) vitamin D supplementation was associated with favorable changes in LF:HF during and after a physiological stressor in subjects with IgA nephropathy and early CKD and (2) 1,25-dihydroxy, rather than 25-hydroxy vitamin D, levels were associated with a graded increase in cardioprotective parasympathetic activity in response to increasing doses of Ang-II. A decrease in parasympathetic activity contributes to SCD risk, and previous studies have suggested that 1,25-dihydroxy vitamin D may be the most robust marker of cardiovascular risk in the CKD population. Together with our present findings, these observations suggest that vitamin D supplementation, with the specific goal of increasing 1,25-dihydroxy vitamin D levels and improving overall cardiovascular risk, may be a potential preventive cardiovascular therapy in this high-risk population. Interestingly, we did not find that vitamin D supplementation was associated with a change in resting (baseline) heart rate variability parameters. Our findings suggest that increasing vitamin D levels are associated with improved modulation of CAT in response to an Ang-II stressor, perhaps highlighting an important interaction between vitamin D and cardiovascular risk specific to populations with increased RAS activity, such as CKD.

Previous studies have suggested that vitamin D, and specifically 1,25-dihydroxy vitamin D, affects the cardiac autonomic system in several ways, including enhancement of electrophysiological β-adrenergic signaling between cardiac myocytes. 1,25-dihydroxy vitamin D crosses the blood–brain barrier and therefore may have physiological implications at the molecular level within the nervous system. In support of our findings, a large cross-sectional study of patients with end-stage kidney disease on hemodialysis reported a positive association between 25-hydroxyvitamin D levels and all-cause and cardiovascular mortality, but that this relationship was no longer observed in patients treated with analogues of 1,25-dihydroxy vitamin D, suggesting that cardioprotection is mediated by the activated form of vitamin D. Similarly, Dobnig et al reported that serum levels of 1,25-dihydroxy vitamin D were independently associated with cardiovascular mortality in a large cohort of patients undergoing coronary angiogram. Our observations of an increase in cardioprotective parasympathetic activity (HF) in response to Ang-II challenge observed only in those subjects with higher levels of 1,25-dihydroxy vitamin D support the findings from these larger studies.

This study has limitations. In humans, vitamin D metabolism is related to that of other minerals and hormones that might influence cardiovascular risk, including parathyroid hormone. Inclusion of these other variables did not significantly change our results, perhaps because of the narrow and clinically insignificant ranges observed in the participants of the study. A decrease in parasympathetic activity contributes to SCD risk, and previous studies have suggested that 1,25-dihydroxy vitamin D may be the most robust marker of cardiovascular risk in the CKD population. Together with our present findings, these observations suggest that vitamin D supplementation, with the specific goal of increasing 1,25-dihydroxy vitamin D levels and improving overall cardiovascular risk, may be a potential preventive cardiovascular therapy in this high-risk population. Interestingly, we did not find that vitamin D supplementation was associated with a change in resting (baseline) heart rate variability parameters. Our findings suggest that increasing vitamin D levels are associated with improved modulation of CAT in response to an Ang-II stressor, perhaps highlighting an important interaction between vitamin D and cardiovascular risk specific to populations with increased RAS activity, such as CKD.

Previous studies have suggested that vitamin D, and specifically 1,25-dihydroxy vitamin D, affects the cardiac autonomic system in several ways, including enhancement of electrophysiological β-adrenergic signaling between cardiac myocytes. 1,25-dihydroxy vitamin D crosses the blood–brain barrier and therefore may have physiological implications at the molecular level within the nervous system. In support of our findings, a large cross-sectional study of patients with end-stage kidney disease on hemodialysis reported a positive association between 25-hydroxyvitamin D levels and all-cause and cardiovascular mortality, but that this relationship was no longer observed in patients treated with analogues of 1,25-dihydroxy vitamin D, suggesting that cardioprotection is mediated by the activated form of vitamin D. Similarly, Dobnig et al reported that serum levels of 1,25-dihydroxy vitamin D were independently associated with cardiovascular mortality in a large cohort of patients undergoing coronary angiogram. Our observations of an increase in cardioprotective parasympathetic activity (HF) in response to Ang-II challenge observed only in those subjects with higher levels of 1,25-dihydroxy vitamin D support the findings from these larger studies.

This study has limitations. In humans, vitamin D metabolism is related to that of other minerals and hormones that might influence cardiovascular risk, including parathyroid hormone. Inclusion of these other variables did not significantly change our results, perhaps because of the narrow and clinically insignificant ranges observed in the participants of the study. A decrease in parasympathetic activity contributes to SCD risk, and previous studies have suggested that 1,25-dihydroxy vitamin D may be the most robust marker of cardiovascular risk in the CKD population. Together with our present findings, these observations suggest that vitamin D supplementation, with the specific goal of increasing 1,25-dihydroxy vitamin D levels and improving overall cardiovascular risk, may be a potential preventive cardiovascular therapy in this high-risk population. Interestingly, we did not find that vitamin D supplementation was associated with a change in resting (baseline) heart rate variability parameters. Our findings suggest that increasing vitamin D levels are associated with improved modulation of CAT in response to an Ang-II stressor, perhaps highlighting an important interaction between vitamin D and cardiovascular risk specific to populations with increased RAS activity, such as CKD.

**Table.** Cardiac Autonomic Tone at Baseline and in Response to Angiotensin-II, Pre–Vitamin D3 supplementation vs Post–Vitamin D3 Supplementation

<table>
<thead>
<tr>
<th>Cardiac Autonomic Parameter</th>
<th>Baseline</th>
<th>3 ng/kg per min</th>
<th>6 ng/kg per min</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>LF</td>
<td>63±5</td>
<td>63±3</td>
<td>63±3</td>
<td></td>
</tr>
<tr>
<td>LF</td>
<td>66±4</td>
<td>56±4</td>
<td>64±4</td>
<td></td>
</tr>
<tr>
<td>HF</td>
<td>32±4</td>
<td>32±3*</td>
<td>32±4</td>
<td></td>
</tr>
<tr>
<td>HF</td>
<td>32±4</td>
<td>32±3</td>
<td>34±4</td>
<td></td>
</tr>
<tr>
<td>LF:HF</td>
<td>1.61±0.2</td>
<td>1.72±0.1*</td>
<td>1.51±0.1†</td>
<td>1.65±0.2†</td>
</tr>
<tr>
<td>BRS, ms/mm Hg§</td>
<td>0.65±0.2</td>
<td>0.39±0.08‡</td>
<td>0.39±0.09*</td>
<td>0.51±0.2</td>
</tr>
</tbody>
</table>

All data are expressed as mean±SE. BRS indicates baroreflex sensitivity; HF, high frequency; LF, low frequency; and LF:HF, low- to high-frequency ratio.

*P<0.05 vs response at baseline.
†P<0.05 vs response at 3 ng/kg per min angiotensin-II dose.
‡P<0.05 postsupplementation vs presupplementation at the same angiotensin-II dose.
§Subgroup analysis, n=5.

**Figure.** Cardiac autonomic response to angiotensin-II (Ang-II) challenge: pre–vitamin D3 supplementation vs post–vitamin D3 supplementation. Error bar: ±1SE. *P<0.05 post-vitamin D3 supplementation vs pre-supplementation response at the same Ang-II dosage; error bar: ±1SE. LF:HF indicates low frequency to high frequency ratio.
our study. Although 1,25-dihydroxy vitamin D has a short t1/2, all serum analyses were conducted at the same central laboratory, thus ensuring the highest accuracy and eliminating intra-assay variability.

We have shown that humans with CKD secondary to IgA nephropathy, but who are otherwise healthy, demonstrate more stable and favorable CAT responses to an acute physiological stressor after oral vitamin D3 supplementation, a phenomenon primarily observed in subjects with greater levels of 1,25-dihydroxy vitamin D. The potential for activated vitamin D as a therapy in mitigating SCD risk in the CKD population merits attention.

Sources of Funding
This work was funded by an Establishment Grant from Alberta Innovates—Health Solutions. Dr Hemmelgarn is the Roy and Vi Baay Chair of Kidney Research at the University of Calgary. Dr Mann is supported by the Canadian Institutes of Health Research. Dr Exner is the Canada Research Chair in Cardiovascular Clinical Trials and receives unrestricted support from GE Healthcare. Funding sources had no role in the design, conduct, or reporting of this study. Drs Hemmelgarn and Ahmed are supported by a joint initiative between Alberta Health and Wellness and the Universities of Alberta and Calgary. Dr Ahmed is supported by Alberta Innovates—Health Solutions.

Disclosures
None.

References
Vitamin D Supplementation Is Associated With Stabilization of Cardiac Autonomic Tone in IgA Nephropathy

Michelle C. Mann, Brenda R. Hemmelgarn, Derek V. Exner, David A. Hanley, Tanvir C. Turin, David C. Wheeler, Darlene Y. Sola, Linda Ellis and Sofia B. Ahmed

_Hypertension_. 2015;66:e4-e6; originally published online June 8, 2015;
doi: 10.1161/HYPERTENSIONAHA.115.05688

_Hypertension_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://hyper.ahajournals.org/content/66/2/e4

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Hypertension_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Hypertension_ is online at:
http://hyper.ahajournals.org/subscriptions/